Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fampridine
- Development stage
- Approved
- Lead developer
- Acorda Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fampridine is an oral, extended-release small molecule potassium channel blocker used to improve walking in adults with multiple sclerosis who have a walking disability. It blocks voltage-gated potassium channels on demyelinated axons, reducing potassium efflux and helping action potentials propagate to improve motor conduction and walking speed. It is marketed in the EU as Fampyra and is closely related to dalfampridine (an extended-release formulation of 4-aminopyridine approved in the US). Typical dosing is 10 mg twice daily about 12 hours apart, and tablets must be swallowed whole due to seizure risk at higher peak concentrations.
- Brand names
- Fampyra
- Other names
- dalfampridine4-aminopyridine4-AP4-pyridinamine
02
Targets
Kir (Inward-rectifier potassium channels)KCNH2 (Voltage-gated potassium channel subfamily H member 2)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)
Beyond the preview
Go deeper on fampridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fampridine.